ArticleJournal of medical case reports2026
Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall cell lung cancer (SCLC) is an aggressive malignancy with a strong propensity for metastasis, often leading to liver metastases associated with severe hepatic dysfunction. Whole-liver irradiation (WLI) is a palliative treatment option for patients with diffuse liver metastases, especially in cases, where systemic chemotherapy is contraindicated. CASE PRESENTATION: We report the case of a 74-year-old Japanese man of East Asian ethnicity with extensive-disease small cell lung cancer (ED-SCLC) and diffuse liver metastases associated with severe hepatic dysfunction following first-line chemotherapy. The patient, initially deemed unsuitable for chemotherapy due to hepatic dysfunction, complained of severe abdominal distension and underwent WLI at a dose of 8 Gy in a single fraction for symptom palliation. Within 2 weeks, the patient showed significant improvement in hepatic function and symptoms. This improvement coincided with sufficient hepatic recovery to permit the subsequent administration of second-line chemotherapy. WLI may provide symptomatic relief for patients with liver metastases and may be associated with hepatic recovery sufficient to allow further systemic treatment in selected cases. Although its role is limited by liver radiation tolerance, advancements in radiotherapy techniques, such as stereotactic body radiation therapy, offer promising complementary approaches. This case highlights the potential role of WLI as a palliative option that may be associated with hepatic recovery sufficient to permit subsequent systemic therapy in selected patients with severe hepatic dysfunction caused by liver metastases.
conclusionsWLI may serve as a palliative option for patients with ED-SCLC and hepatic dysfunction and, in selected cases, may be associated with hepatic recovery sufficient to permit subsequent systemic treatment. Further research is warranted to establish optimal protocols and patient selection criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.